» Articles » PMID: 29065044

Osteogenesis of Crouzon-Mutated Cells in an Experimental Model

Overview
Date 2017 Oct 25
PMID 29065044
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Crouzon syndrome is an autosomal-dominant congenital disease due to a mutation in the fibroblast growth factor receptor 2 protein. The purpose of this study is to evaluate wound-healing potential of Crouzon osteoblasts and adipose-derived stem cells (ADSCs) in a murine model. Parietal skull defects were created in Crouzon and mature wild-type (WT) CD-1 mice. One group of WT and Crouzon mice were left untreated. Another group was transplanted with both WT and Crouzon adipose-derived stem cells. Additional groups compared the use of a fibrin glue scaffold and periosteum removal. Skulls were harvested from each group and evaluated histologically at 8-week and/or 16-week periods. Mean areas of defect were quantified and compared via ANOVA F-test. The average area of defect after 8 and 16 weeks in untreated Crouzon mice was 15.37 ± 1.08 cm and 16.69 ± 1.51 cm, respectively. The average area of the defect in untreated WT mice after 8 and 16 weeks averaged 14.17 ± 1.88 cm and 14.96 ± 2.26 cm, respectively. WT mice with autologous ADSCs yielded an average area of 15.35 ± 1.34 cm after 16 weeks while Crouzon mice with WT ADSCs healed to an average size of 12.98 ± 1.89 cm. Crouzon ADSCs transplanted into WT mice yielded an average area of 15.47 ± 1.29 cm while autologous Crouzon ADSCs yielded an area of 14.22 ± 3.32 cm. ANOVA F-test yielded P = .415. The fibroblast growth factor receptor 2 mutation in Crouzon syndrome does not promote reossification of critical-sized defects in mature WT and Crouzon mice. Furthermore, Crouzon ADSCs do not possess osteogenic advantage over WT ADSCs.

References
1.
Levi B, James A, Nelson E, Peng M, Wan D, Commons G . Acute skeletal injury is necessary for human adipose-derived stromal cell-mediated calvarial regeneration. Plast Reconstr Surg. 2011; 127(3):1118-1129. PMC: 3073240. DOI: 10.1097/PRS.0b013e318205f274. View

2.
Smith D, Cooper G, Afifi A, Mooney M, Cray J, Rubin J . Regenerative surgery in cranioplasty revisited: the role of adipose-derived stem cells and BMP-2. Plast Reconstr Surg. 2011; 128(5):1053-1060. DOI: 10.1097/PRS.0b013e31822b65e4. View

3.
Szpalski C, Barr J, Wetterau M, Saadeh P, Warren S . Cranial bone defects: current and future strategies. Neurosurg Focus. 2010; 29(6):E8. DOI: 10.3171/2010.9.FOCUS10201. View

4.
Cicciu M, Herford A, Juodzbalys G, Stoffella E . Recombinant human bone morphogenetic protein type 2 application for a possible treatment of bisphosphonates-related osteonecrosis of the jaw. J Craniofac Surg. 2012; 23(3):784-8. DOI: 10.1097/SCS.0b013e31824dbdd4. View

5.
Liu J, Kyung Nam H, Wang E, Hatch N . Further analysis of the Crouzon mouse: effects of the FGFR2(C342Y) mutation are cranial bone-dependent. Calcif Tissue Int. 2013; 92(5):451-66. PMC: 3631296. DOI: 10.1007/s00223-013-9701-2. View